CM
MDGL icon

Cornerstone Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Cornerstone Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-40
Closed -$3.92K – 254
2022
Q1 		$3.92K Buy
+40
New +$3.37K ﹤0.01% 202

Other funds holding MDGL

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Cornerstone Management's MDGL Position: Q2 2022 in Review

Cornerstone Management sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2022, closing a stake of 40 shares — an estimated $3.92K sold.

Cornerstone Management first reported a position in MDGL in Q1 2022 and held it in 1 quarter. The position peaked at $3.92K in Q1 2022. 138 funds tracked by Wall St. Rank hold MDGL as of Q2 2022.

  • Cornerstone Management reported no remaining Madrigal Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Cornerstone Management sold 40 Madrigal Pharmaceuticals shares in Q2 2022, an estimated $3.92K.
  • Cornerstone Management first reported a position in Madrigal Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Cornerstone Management's Madrigal Pharmaceuticals position peaked at $3.92K in Q1 2022.
  • 138 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2022.

Based on Cornerstone Management's 13F filing for Q2 2022, filed 9 May 2023.